{"DataElement":{"publicId":"3298921","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Therapy Type","preferredDefinition":"Text name of  the agent administered to an individual as part of Graft vs Host Disease (GVHD) prophylaxis.","longName":"GVHD_PREV_INT_TX_TP","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2681983","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Administration","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","longName":"GVHD_PRV_ADMN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2681981","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:An attempt to prevent disease.","longName":"C3063:C15843","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1889B5-158A-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-14","modifiedBy":"ONEDATA","dateModified":"2007-09-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320521","version":"1","preferredName":"Administration","preferredDefinition":"The act of administration.","longName":"C25409","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-053F-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A1889B5-1598-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-14","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298920","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Therapy Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin._Therapeutic, nutritional, environmental, social and or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Type; a subdivision of a particular kind of thing.","longName":"GVHD_PRV_INT_TX_TP","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Antithymocyte Globulin (ATG)","valueDescription":"Anti-Thymocyte Globulin","ValueMeaning":{"publicId":"3253646","version":"1","preferredName":"Anti-Thymocyte Globulin","longName":"3253646","preferredDefinition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Thymocyte Globulin","conceptCode":"C278","definition":"Purified gamma globulin, with immunosuppressive activity. Obtained from animals that have been immunized with human thymocytes, antithymocyte globulin (ATG) specifically recognizes and destroys T lymphocytes. Although not completely understood, the mechanism of action appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering ATG with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host (GVH) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-7AB2-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C6D9F6-B4F7-1EF5-E040-BB89AD433914","beginDate":"2008-08-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Cyclosporine","valueDescription":"Cyclosporine","ValueMeaning":{"publicId":"2567427","version":"1","preferredName":"Cyclosporine","longName":"2567427","preferredDefinition":"11-residue cyclic peptide produced by certain fungi which has antifungal and T cell specific immunosuppressive properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclosporine","conceptCode":"C406","definition":"A natural cyclic polypeptide immunosuppressant isolated from the fungus Beauveria nivea. The exact mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D470-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C6D9F6-B501-1EF5-E040-BB89AD433914","beginDate":"2008-08-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Tacrolimus","valueDescription":"Tacrolimus (Prograf, Protopic Ointment, Advagraf)","ValueMeaning":{"publicId":"2775673","version":"1","preferredName":"Tacrolimus (Prograf, Protopic Ointment, Advagraf)","longName":"2775673","preferredDefinition":"A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tacrolimus","conceptCode":"C1311","definition":"A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-01E0-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C6D9F6-B50C-1EF5-E040-BB89AD433914","beginDate":"2008-08-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Methotrexate (MTX)","valueDescription":"Methotrexate Administration","ValueMeaning":{"publicId":"2775672","version":"1","preferredName":"Methotrexate Administration","longName":"2775672","preferredDefinition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.: The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-01BB-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"MAESKEB","dateModified":"2020-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C6D9F6-B516-1EF5-E040-BB89AD433914","beginDate":"2008-08-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Mycophenolate Mofetil (CellCept)","valueDescription":"Mycophenolate Mofetil","ValueMeaning":{"publicId":"3253642","version":"1","preferredName":"Mycophenolate Mofetil","longName":"3253642","preferredDefinition":"The mopholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate Mofetil","conceptCode":"C1468","definition":"The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81EFF99-79F9-7C87-E040-BB89AD430597","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-07-15","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C6D9F6-B52A-1EF5-E040-BB89AD433914","beginDate":"2008-08-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"T-Cell Depletion","valueDescription":"T-cell depletion","ValueMeaning":{"publicId":"2568175","version":"1","preferredName":"T-cell depletion","longName":"2568175","preferredDefinition":"T-cell depletion","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Depletion Therapy","conceptCode":"C15699","definition":"Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft or peripheral blood stem cell graft from a donor may reduce the chance of an immune reaction against the recipient's tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D75C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-27","modifiedBy":"SBREXT","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C75B1F-DF2A-A8AF-E040-BB89AD436668","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Alemtuzumab (Campath)","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C75B1F-DF3F-A8AF-E040-BB89AD436668","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Other (specify)","valueDescription":"Other Agent","ValueMeaning":{"publicId":"3202962","version":"1","preferredName":"Other Agent","longName":"3202962","preferredDefinition":"Different than the one(s) previously specified or mentioned.: An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E727F7D-AEBB-154D-E040-BB89AD4315DA","latestVersionIndicator":"Yes","beginDate":"2011-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"MAESKEB","dateModified":"2020-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C75B1F-DF15-A8AF-E040-BB89AD436668","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C75B1F-DF49-A8AF-E040-BB89AD436668","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"2757911","version":"1","preferredName":"Cyclophosphamide","longName":"2757911","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83F7-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C75B1F-DF53-A8AF-E040-BB89AD436668","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"2760061","version":"1","preferredName":"Sirolimus","longName":"2760061","preferredDefinition":"A drug used to help prevent rejection of organ and bone marrow transplants by the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE455C3-3ABF-5319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0C75B1F-DF5D-A8AF-E040-BB89AD436668","beginDate":"2008-08-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","deletedIndicator":"No"},{"value":"Anti-TNF Agent","valueDescription":"Anti-Tumor Necrosis Factor Therapy","ValueMeaning":{"publicId":"3233636","version":"1","preferredName":"Anti-Tumor Necrosis Factor Therapy","longName":"3233636","preferredDefinition":"Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-Tumor Necrosis Factor Therapy","conceptCode":"C15577","definition":"Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A27C18C9-DC1E-820E-E040-BB89AD432300","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E27A-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Anti-T Cell Antibody","valueDescription":"T-Lymphocyte Antibody Inhibition","ValueMeaning":{"publicId":"3861599","version":"1","preferredName":"T-Lymphocyte Antibody Inhibition","longName":"3861599","preferredDefinition":"One type of white blood cell that attacks virus-infected cells, foreign cells, and cancer cells.  T cells also produce a number of substances that regulate the immune response.: (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.: The interference with or prevention of an action or response even though the stimulus for that action or response is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48D458D-E288-886E-E040-BB89AD43672D","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E2A1-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":"Corticosteroid","ValueMeaning":{"publicId":"2563882","version":"1","preferredName":"Corticosteroid","longName":"2563882v1.00","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C697-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"KUMMEROA","dateModified":"2023-09-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E2AB-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Calcineurin Inhibitors","valueDescription":"Calcineurin Inhibition","ValueMeaning":{"publicId":"3861602","version":"1","preferredName":"Calcineurin Inhibition","longName":"3861602","preferredDefinition":"Ubiquitous heterodimeric human Calcineurin is Ca(2+)/calmodulin-regulated protein phosphatase involved in many biologic activities as a modifier of phosphorylation status. Composed of widely expressed or tissue-restricted 55-60-kDa calmodulin-binding catalytic subunit (PPP Phosphatase/PP-2B Family) and conserved 19-kD Ca(2+)-sensitive regulatory subunit, Calcineurin appears to regulate glycolytic metabolism, nuclear translocation of NFATC1 transcription factor, sperm motility, and dopaminergic signal transduction and NMDA receptor-dependent synaptic plasticity. (NCI): The interference with or prevention of an action or response even though the stimulus for that action or response is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcineurin","conceptCode":"C17275","definition":"Ubiquitous heterodimeric human Calcineurin is Ca(2+)/calmodulin-regulated protein phosphatase involved in many biologic activities as a modifier of phosphorylation status. Composed of widely expressed or tissue-restricted 55-60-kDa calmodulin-binding catalytic subunit (PPP Phosphatase/PP-2B Family) and conserved 19-kD Ca(2+)-sensitive regulatory subunit, Calcineurin appears to regulate glycolytic metabolism, nuclear translocation of NFATC1 transcription factor, sperm motility, and dopaminergic signal transduction and NMDA receptor-dependent synaptic plasticity. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Inhibition","conceptCode":"C42791","definition":"The interference with or prevention of an action or response even though the stimulus for that action or response is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48D458D-E2B9-886E-E040-BB89AD43672D","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E2D2-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Extra-Corporeal Photophoresis (ECP)","valueDescription":"Extracorporeal Photopheresis","ValueMeaning":{"publicId":"2777671","version":"1","preferredName":"Extracorporeal Photopheresis","longName":"2777671","preferredDefinition":"A procedure in which blood is removed from the body and treated with ultraviolet light and drugs that become active when exposed to light. The blood is then returned to the body. It is being studied in the treatment of some blood and bone marrow diseases and graft-vs-host disease (GVHD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extracorporeal Photopheresis","conceptCode":"C62729","definition":"A procedure which combines apheresis and photodynamic therapy, resulting in blood being treated with a photosensitizing agent and subsequently irradiated with specified wavelengths of light to achieve an effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"554B1B7C-0FF8-6EED-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E2E6-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Hydroxychloroquine","valueDescription":"Hydroxychloroquine","ValueMeaning":{"publicId":"3379074","version":"1","preferredName":"Hydroxychloroquine","longName":"3379074","preferredDefinition":"A substance that decreases immune responses in the body.  It is used to treat some autoimmune diseases, and is being studied as a treatment for graft-versus-host disease. Hydroxychloroquine belongs to the family of drugs called antiprotozoals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxychloroquine","conceptCode":"C557","definition":"A 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B914C2F8-AF6A-3067-E040-BB89AD433056","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E2F0-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"2738482","version":"1","preferredName":"Rituximab","longName":"2738482","preferredDefinition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F890-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E2FA-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"2577064","version":"1","preferredName":"None","longName":"2577064","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-22","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E48D458D-E304-886E-E040-BB89AD43672D","beginDate":"2013-08-22","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","deletedIndicator":"No"},{"value":"Mycophenolate","valueDescription":"Mycophenolate","ValueMeaning":{"publicId":"2578310","version":"1","preferredName":"Mycophenolate","longName":"2578310","preferredDefinition":"The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycophenolate","conceptCode":"C29272","definition":"The morpholinoethyl ester of mycophenolic acid (MPA).  As an immunosuppressive agent in vivo, the active metabolite mycophenolate reversibly inhibits inosine 5'-monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanine nucleotides, thereby retarding T-cell and B-cell proliferation.  MPA displays high lymphocyte specificity and cytotoxicity because lymphocyte metabolism is highly dependent on both salvage and de novo synthesis of guanine nucleotides. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEF3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4E6DCBF-18B6-667F-E040-BB89AD431523","beginDate":"2014-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-18","modifiedBy":"ONEDATA","dateModified":"2014-03-18","deletedIndicator":"No"},{"value":"Methylprednisolone","valueDescription":"Methylprednisolone","ValueMeaning":{"publicId":"2578269","version":"1","preferredName":"Methylprednisolone","longName":"2578269","preferredDefinition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone","conceptCode":"C647","definition":"A synthetic corticosteroid with anti-inflammatory and immunomodulating properties.  Methylprednisolone binds to and activates specific nuclear receptors, resulting in altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FECA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4E6DCBF-18C0-667F-E040-BB89AD431523","beginDate":"2014-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-18","modifiedBy":"ONEDATA","dateModified":"2014-03-18","deletedIndicator":"No"},{"value":"Monoclonal antibodies","valueDescription":"Monoclonal Antibody","ValueMeaning":{"publicId":"4232285","version":"1","preferredName":"Monoclonal Antibody","longName":"4232285","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4E6DCBF-18CA-667F-E040-BB89AD431523","latestVersionIndicator":"Yes","beginDate":"2014-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F4E6DCBF-18E2-667F-E040-BB89AD431523","beginDate":"2014-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-18","modifiedBy":"ONEDATA","dateModified":"2014-03-18","deletedIndicator":"No"},{"value":"Abatacept","valueDescription":"Abatacept","ValueMeaning":{"publicId":"6429536","version":"1","preferredName":"Abatacept","longName":"6429536","preferredDefinition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abatacept","conceptCode":"C28898","definition":"A soluble fusion protein consisting of the extracellular domain of human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) with immunosuppressive activity. Abatacept binds CD80 and CD86 on antigen presenting cells (APCs), blocking interaction with CD28 on T lymphocytes, which initiates a co-stimulatory signal required for full activation of T lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AF6CD8-495C-4E44-E053-F662850AD113","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"ONEDATA","dateModified":"2018-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B7C7377-E0F7-0202-E053-F662850A097C","beginDate":"2020-01-06","endDate":null,"createdBy":"MAESKEB","dateCreated":"2020-01-06","modifiedBy":"ONEDATA","dateModified":"2020-01-06","deletedIndicator":"No"},{"value":"Brutinib (Imbruvica)","valueDescription":"Ibrutinib","ValueMeaning":{"publicId":"5588944","version":"1","preferredName":"Ibrutinib","longName":"5588944","preferredDefinition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-93BA-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAE408A2-E458-4FA9-E053-4EBD850ABA76","beginDate":"2022-03-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-23","modifiedBy":"ONEDATA","dateModified":"2022-03-23","deletedIndicator":"No"},{"value":"UVA1","valueDescription":"UVA1 Phototherapy","ValueMeaning":{"publicId":"8119694","version":"1","preferredName":"UVA1 Phototherapy","longName":"8119694","preferredDefinition":"Phototherapy that uses UV light in the 340-400nm range.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"UVA1 Phototherapy","conceptCode":"C186479","definition":"Phototherapy that uses UV light in the 340-400nm range.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAE408A2-E427-4FA9-E053-4EBD850ABA76","latestVersionIndicator":"Yes","beginDate":"2022-03-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-23","modifiedBy":"ONEDATA","dateModified":"2022-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAE408A2-E442-4FA9-E053-4EBD850ABA76","beginDate":"2022-03-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-23","modifiedBy":"ONEDATA","dateModified":"2022-03-23","deletedIndicator":"No"},{"value":"Daclizumab","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"5127373","version":"1","preferredName":"Daclizumab","longName":"5127373","preferredDefinition":"A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-F951-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAE408A2-E46C-4FA9-E053-4EBD850ABA76","beginDate":"2022-03-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-23","modifiedBy":"ONEDATA","dateModified":"2022-03-23","deletedIndicator":"No"},{"value":"Vedolizumab (Entyvio)","valueDescription":"Vedolizumab","ValueMeaning":{"publicId":"8115529","version":"1","preferredName":"Vedolizumab","longName":"8115529v1.00","preferredDefinition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vedolizumab","conceptCode":"C95798","definition":"A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3E8E-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"GDEEN","dateModified":"2023-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3EA9-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Tocilizumab","valueDescription":"Tocilizumab","ValueMeaning":{"publicId":"4618052","version":"1","preferredName":"Tocilizumab","longName":"4618052","preferredDefinition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. Il-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders and certain types of cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tocilizumab","conceptCode":"C84217","definition":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0953B289-65BB-6299-E050-BB89AD4328C8","latestVersionIndicator":"Yes","beginDate":"2014-12-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3EB3-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Ruxolitinib (Jakafi)","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"5125106","version":"1","preferredName":"Ruxolitinib","longName":"5125106","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C0D42D8-A87E-AEAF-E050-BB89AD430679","latestVersionIndicator":"Yes","beginDate":"2016-02-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3EC9-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Natalizumab (PUVA)","valueDescription":"Natalizumab","ValueMeaning":{"publicId":"8115531","version":"1","preferredName":"Natalizumab","longName":"8115531","preferredDefinition":"A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natalizumab","conceptCode":"C77862","definition":"A humanized recombinant IgG4 monoclonal antibody directed against the alpha4 subunit of the integrins alpha4beta1and alpha4beta7 with immunomodulating, anti-inflammatory, and potential antineoplastic activities.  Natalizumab binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins expressed on the surface of all leukocytes except neutrophils, inhibiting the alpha4-mediated adhesion of leukocytes to counter-receptor(s) such as vascular cell adhesion molecule-1 (VCAM-1); natalizumab-mediated disruption of VCAM-1 binding by these integrins may prevent the transmigration of leukocytes across the endothelium into inflamed parenchymal tissue.  Integrins are cellular adhesion molecules (CAMs) that are upregulated in various types of cancer and some autoimmune diseases; alpha4beta1 integrin (VLA4) has been implicated in the survival of myeloma cells, possibly by mediating their adhesion to stromal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3ED6-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3EF1-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Mesenchymal Stem Cells","valueDescription":"Mesenchymal Stem Cell","ValueMeaning":{"publicId":"4197222","version":"1","preferredName":"Mesenchymal Stem Cell","longName":"4197222","preferredDefinition":"An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mesenchymal Stem Cell","conceptCode":"C43423","definition":"An undifferentiated stromal cell with the ability to develop into the cells that form distinct mesenchymal tissues; such as bone, muscle, connective tissue, blood vessels, and lymphatic tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F1A516-3B13-2DD9-E040-BB89AD434115","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"COLBERTM","dateCreated":"2014-03-06","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3F05-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Fecal Microbial Transplant","valueDescription":"Feces Microorganism Transplantation","ValueMeaning":{"publicId":"8115532","version":"1","preferredName":"Feces Microorganism Transplantation","longName":"8115532","preferredDefinition":"The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.: A microscopic organism. The term microorganism may refer to a prokaryote or eukaryote, and may be a unicellular or multicellular organism. All taxonomic kingdoms contain microorganisms.: Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Feces","conceptCode":"C13234","definition":"The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Microorganism","conceptCode":"C14329","definition":"A microscopic organism. The term microorganism may refer to a prokaryote or eukaryote, and may be a unicellular or multicellular organism. All taxonomic kingdoms contain microorganisms.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3F13-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3F2E-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Etanercept (Adcetris)","valueDescription":"Etanercept","ValueMeaning":{"publicId":"5126589","version":"1","preferredName":"Etanercept","longName":"5126589","preferredDefinition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C25600F-CB7A-BDDC-E050-BB89AD434CE4","latestVersionIndicator":"Yes","beginDate":"2016-02-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3F44-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Pentostatin","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"5127413","version":"1","preferredName":"Pentostatin","longName":"5127413","preferredDefinition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAA7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3F4F-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Infliximab","valueDescription":"Infliximab","ValueMeaning":{"publicId":"3235990","version":"1","preferredName":"Infliximab","longName":"3235990","preferredDefinition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis.  Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-820D-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3F59-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"},{"value":"Antilymphocyte Globulin (ALG)","valueDescription":"Antilymphocyte Serum","ValueMeaning":{"publicId":"8115533","version":"1","preferredName":"Antilymphocyte Serum","longName":"8115533","preferredDefinition":"Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antilymphocyte Serum","conceptCode":"C62577","definition":"Immunoglobulins raised xenogeneically against lymphocyte populations.  It is used both as a test for histocompatibility and in conjunction with other immunosuppressive agents to suppress rejection of grafts or organ transplants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DAD1A896-3F65-0376-E053-4EBD850A20B1","latestVersionIndicator":"Yes","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DAD1A896-3F80-0376-E053-4EBD850A20B1","beginDate":"2022-03-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2022-03-22","modifiedBy":"ONEDATA","dateModified":"2022-03-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298919","version":"1","preferredName":"Graft Versus Host Disease Preventive Intervention Therapeutic Procedure Type","preferredDefinition":"An incompatibility reaction (which may be fatal) in a subject (host) of low immunological competence (deficient lymphoid tissue) who has been the recipient of immunologically competent lymphoid tissue from a donor who lacks at least one antigen possessed by the recipient host; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess the antigen not possessed by the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.:An attempt to prevent disease.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Type; a subdivision of a particular kind of thing.","longName":"C3063:C15843:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft Versus Host Disease","conceptCode":"C3063","definition":"A reaction, which may be fatal, in an immunocompromised subject (host) who has received an antigenically incompatible tissue transplant (graft) from an immunocompetent donor. The reaction is secondary to the activation of the transplanted cells against those host tissues that express an antigen not expressed by the donor, and is seen most commonly following bone marrow transplantation; acute disease is seen after 5-40 days, and chronic disease occurs weeks to months after transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0C6D9F6-B4C8-1EF5-E040-BB89AD433914","latestVersionIndicator":"Yes","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ONEDATA","dateModified":"2011-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0C6D9F6-B4D9-1EF5-E040-BB89AD433914","latestVersionIndicator":"Yes","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"MAESKEB","dateModified":"2022-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"}],"ReferenceDocuments":[{"name":"GVHD Prophylaxis","type":"Preferred Question Text","description":"GVHD Prophylaxis","url":null,"context":"CCR"},{"name":"COG CRF Text1","type":"Alternate Question Text","description":"Type of GVHD prophylaxis:","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Were any of these medications used for GVHD treatment/ prophylaxis?","url":null,"context":"COG"},{"name":"Specify the recipient's GVHD prophylaxis","type":"Alternate Question Text","description":"Specify the recipient's GVHD prophylaxis","url":null,"context":"NHLBI"},{"name":"Specify the recipient's GVHD prophylaxis","type":"Application Standard Question Text","description":"Specify the recipient's GVHD prophylaxis","url":null,"context":"NHLBI"},{"name":"COG CRF TEXT 3","type":"Alternate Question Text","description":"Did patient receive GVHD prophylaxis?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0C75B1F-DF67-A8AF-E040-BB89AD436668","latestVersionIndicator":"Yes","beginDate":"2011-11-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-11-02","modifiedBy":"ZHWENDY","dateModified":"2022-07-20","changeDescription":"Curated to support NCI CCR Transplantation trial","administrativeNotes":"7/20/2022: fixed the box symbol in AQT.wz","unresolvedIssues":null,"deletedIndicator":"No"}}